fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Grain & citrus fibre

All products: not a benefit

Fibyrax · DIN 00779768 · · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-14 — choose a marketed DIN from the same-category list.Discontinued July 14, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-07-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Fibyrax · DIN 00779768 Manufacturer: Lederle Division-of Cyanamid Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1998-07-14 · brand FIBYRAX TAB 469MG · ATC A06AC07 TRITICUM (WHEAT FIBRE) · form Tablet · route Oral · ingredients FIBER 469 MG/TAB · company Lederle consumer health products · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Fibyrax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00779768)

Source record
DIN 00779768: Fibyrax Raw flags: notABenefit=Y, sec3=Y Item: 561200037; group id 650; item number 1632; lccId None; manufacturer id LED Source form: Tab; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00779768 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9251
Interchangeable products
Novo-Fibre · DIN 00595829 · $0.0706
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00779768
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 14, 1998 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (A06A): coverage varies; not interchangeable

  • Bisacodyl (Dulcolax): general benefit
  • Docusate dioctyl sulfosuccinate (Docusate Sodium): general benefit
  • Lactulose (PMS-Lactulose): general benefit
  • Citric acid + oxide + picosulfate (Pico-Salax): general benefit
  • Mineral oil (Fleet Enema Mineral Oil): general benefit
Other drugs in the same formulary class (56:12 Cathartics) and how they are covered

Matched class: 56:12 Cathartics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BISACODYL, DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE), LACTULOSE, MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE, MINERAL OIL, PSYLLIUM MUCILLOID, SENNOSIDES A & B, SODIUM BIPHOSPHATE & SODIUM PHOSPHATE 56:12 Cathartics

BISACODYL

· 5 products · General benefit · strengths: 5mg, 10mg · Ent Tab, Sup

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)

· 6 products · General benefit · strengths: 100mg, 4mg/mL, 10mg/mL · Cap, O/L

LACTULOSE

· 1 products · General benefit · strengths: 667mg/mL · O/L

MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE

· 2 products · General benefit · strengths: 3.5g & 12g & 10mg · Pd for Sol-12g Sachet

MINERAL OIL

· 1 products · General benefit · strengths: 100% · Enema

PSYLLIUM MUCILLOID

· 1 products · General benefit · strengths: · Oral Pd

SENNOSIDES A & B

· 2 products · General benefit · strengths: 8.6mg · Tab

SODIUM BIPHOSPHATE & SODIUM PHOSPHATE

· 2 products · General benefit · strengths: 160mg & 60mg/mL · Ped Rect Sol, Rect Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:12
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Fibyrax: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026